Keywords: مهار کننده MEK; Embryonic stem cells; Pluripotency; Gsk3β inhibitor; MEK inhibitor; X-chromosome-linked genes;
مقالات ISI مهار کننده MEK (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده MEK; Ovarian cancer; Low-grade serous; MEK inhibitor; MAP kinase;
Synergistic anti-proliferative effects of mTOR and MEK inhibitors in high-grade chondrosarcoma cell line OUMS-27
Keywords: مهار کننده MEK; Chondrosarcoma; OUMS-27; mTOR inhibitor; Rapamycin; MEK inhibitor; PD 0325901; Dual inhibitor; Synergistic effect;
How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma
Keywords: مهار کننده MEK; AZD6244; Binimetinib; MEK162; MEK inhibitor; Ocular melanoma; Selumetinib; Sotrastaurin; Trametinib; Uveal melanoma; Uveal neoplasms;
Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse
Keywords: مهار کننده MEK; Neurofibromatosis type 1 (NF1); Muscle weakness; Myopathy; MEK inhibitor;
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Keywords: مهار کننده MEK; Melanoma; Chemotherapy; Vemurafenib; Dabrafenib; Trametinib; Metastatic; Unresectable; BRAF inhibitor; MEK inhibitor; Progression free survival (PFS); Median progression free survival;
The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression
Keywords: مهار کننده MEK; Influenza A virus; Anti-Influenza agent; MEK inhibitor; Trametinib (GSK-1120212); Viral replication; Cytokine expression;
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome
Keywords: مهار کننده MEK; Dabrafenib; melanoma; trametinib; podocyte injury; glomerulopathy; nephrotic syndrome; BRAF inhibitor; MEK inhibitor; targeted cancer therapy; BRAF signaling pathway; proteinuria; PLCε1; renal biopsy; nephrotoxicity; case report;
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)
Keywords: مهار کننده MEK; Type I epithelial ovarian cancer; MEK inhibitor; Molecular profiling;
Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma
Keywords: مهار کننده MEK; AMPK; AMP-activated kinase; BRAFi; BRAF inhibitor; ERK; extracellular signal-regulated kinase; ERKi; ERK inhibitor; PGC1α; peroxisome proliferator-activated receptor gamma, coactivator 1-α; MEK; MAPK/ERK kinase; MEKi; MEK inhibitor; mTOR; mechanistic ta
Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer
Keywords: مهار کننده MEK; PI3K inhibitor; MEK inhibitor; K-Ras; Biliary tract cancer;
Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation
Keywords: مهار کننده MEK; Cardiomyopathy; Emery-Dreifuss muscular dystrophy; Extracellular signal-regulated kinase; Lamin; MEK inhibitor; Mitogen-activated protein kinase;
(Neo)adjuvant systemic therapy for melanoma
Keywords: مهار کننده MEK; Cutaneous melanoma; High risk melanoma; Melanoma; Adjuvant; Neoadjuvant; Immunotherapy; Anti CTLA-4; Ipilimumab; BRAF inhibitor; Vemurafenib; Dabrafenib; MEK inhibitor; Trametinib; Cobimetinib; Anti PD1; T-VEC; Tamilogene Laherparepvec; Review;
Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies
Keywords: مهار کننده MEK; Antiproliferative; Breast cancer; Hecogenin; MEK inhibitor; Rational design; Thiosemicarbazones;
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
Keywords: مهار کننده MEK; Trametinib; MEK inhibitor; NSCLC; KRAS mutations;
PAPS PaperMEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy
Keywords: مهار کننده MEK; Neuroblastoma; RAS-ERK pathway; MEK inhibitor; RAF/MEK inhibitor; Trametinib; CH5126766;
Choriorétinopathie séreuse multifocale secondaire à l'utilisation des inhibiteurs MEK : illustration et exemple de prise en charge à travers 2 cas
Keywords: مهار کننده MEK; Choriorétinopathie; Inhibiteur MEK; Sélumetinib; Traitement des cancers; Effet indésirable; Chorioretinopathy; MEK inhibitor; Selumetinib; Cancer treatment; Adverse effect;
Original ResearchA phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
Keywords: مهار کننده MEK; MEK inhibitor; Phase I; Pharmacodynamics; Pharmacokinetics; Optimal biological dose;
Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents
Keywords: مهار کننده MEK; 3-Benzyl-1,3-benzoxazine-2,4-dione; MEK inhibitor; EV71; Antiviral agent;
The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
Keywords: مهار کننده MEK; NSCLC; HSP90 inhibitor; MEK inhibitor; KRAS mutation; Combination therapy;
Pathobiological mechanisms of peritoneal adhesions: The mesenchymal transition of rat peritoneal mesothelial cells induced by TGF-β1 and IL-6 requires activation of Erk1/2 and Smad2 linker region phosphorylation
Keywords: مهار کننده MEK; Peritoneal adhesions; TGF-β; IL-6; Mesothelial/mesenchymal transition; Erk1/2; MEK inhibitor;
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Keywords: مهار کننده MEK; Selumetinib; endometrial cancer; MEK inhibitor; toxicity; Phase II trial;
Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence
Keywords: مهار کننده MEK; Trametinib; GSK 1120212; MEK inhibitor; Radiosensitization; Senescence;
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
Keywords: مهار کننده MEK; BRAF inhibitor; MEK inhibitor; Melanoma; MAPK pathway; Upstream inhibition; Downstream inhibition; Sequenced administration;
Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAFV600E mutation and its possible molecular mechanism
Keywords: مهار کننده MEK; Urinary-type plasminogen activator; Papillary thyroid cancer; BRAF; ERK1/2; MEK inhibitor
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
Keywords: مهار کننده MEK; cutaneous adverse event; histology; inflammation; rash; squamous cell carcinoma; therapy; AK; actinic keratosis; bid; twice a day; BRAFi; BRAF inhibitor; CI; confidence interval; FDA; Food and Drug Administration; KA; keratoacanthoma; MAPK; mitogen-activa
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Keywords: مهار کننده MEK; Gemcitabine; MEK inhibitor; Trametinib; Pancreas; Randomised
Thérapies moléculaires ciblées (hors immunothérapie)
Keywords: مهار کننده MEK; métastatique; inhibiteur de BRAF; inhibiteur de MEK; inhibiteur de cKIT; metastatic melanoma; BRAF inhibitor; MEK inhibitor; cKIT inhibitor;
Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models
Keywords: مهار کننده MEK; ERK pathway; MEK inhibitor; HDAC inhibitor; Combination therapy; Synergistic drug interaction;
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Keywords: مهار کننده MEK; Trametinib; MAP kinase; Gemcitabine; MEK inhibitor; GSK1120212;
Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells
Keywords: مهار کننده MEK; EGF; epidermal growth factor; EMT; epithelial to mesenchymal transition; ERK1/2; extracellular-signal regulated kinase 1/2; FBS; fetal bovine serum; IGF-1; insulin-like growth factor-1; LY294002; PI3K inhibitor; MAPK; mitogen-activated protein kinase; MEK
Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro
Keywords: مهار کننده MEK; MEK inhibitor; Tamiflu; Oseltamivir-carboxylate; Influenza A virus
Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy
Keywords: مهار کننده MEK; MEK inhibitor; Kinase; Oncology; Dihydroindolone; Dihydroindolizinone
Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells
Keywords: مهار کننده MEK; MEK inhibitor; Lung cancer; Actin cytoskeleton; Invasion
Novel zebrafish model reveals a critical role for MAPK in lymphangiogenesis
Keywords: مهار کننده MEK; Lymphatic disorders; Primary lymphedema; VEGF; VEGF receptors; MEK inhibitor; Lymphangiogenesis
Mechanical allodynia but not thermal hyperalgesia is impaired in mice deficient for ERK2 in the central nervous system
Keywords: مهار کننده MEK; ERK; MEK inhibitor; Neuropathic pain; Allodynia; Spinal cord; Hyperalgesia;
Selective inhibition of extracellular signal-regulated kinases 1/2 blocks nerve growth factor to brain-derived neurotrophic factor signaling and suppresses the development of and reverses already established pain behavior in rats
Keywords: مهار کننده MEK; AZD6244; neuropathic pain; drug therapy; MEK inhibitor; NGF-BDNF signalingBDNF, brain-derived neurotrophic factor; CA-MEK1, constitutively active-MEK1; CCI, chronic constriction injury; DRG, dorsal root ganglion; EDTA, ethylenediaminetetraacetic acid; ERK
Role of Additional Novel Therapies in Myeloproliferative Neoplasms
Keywords: مهار کننده MEK; JAK2-V617F; HDAC inhibitor; hsp90 inhibitors; PI3K/AKT inhibitor; MEK inhibitor; Myeloproliferative neoplasms;
MEK inhibitors suppress β-amyloid production by altering the level of a β-C-terminal fragment of amyloid precursor protein in neuronal cells
Keywords: مهار کننده MEK; AD, Alzheimer’s disease; Aβ, β-amyloid peptide; APP, amyloid precursor protein; α- and β-CTF, α- and β-C-terminal fragment; swAPP, Swedish mutant APPAlzheimer’s disease; Amyloid precursor protein; β-Amyloid; MEK inhibitor; Neuroblastoma; Proteasome
A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
Keywords: مهار کننده MEK; AZD6244; Non-small cell lung cancer; Phase II; Clinical trial; MEK inhibitor
ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFα release
Keywords: مهار کننده MEK; TNFα; GM-CSF; LPS; p38 inhibitor; MEK inhibitor
Nociceptin and its metabolite attenuate U0126-induced memory impairment through a nociceptin opioid peptide (NOP) receptor-independent mechanism
Keywords: مهار کننده MEK; Nociceptin/orphanin FQ; NOP receptor; Nociceptin metabolite; ERK; Memory U0126; MEK inhibitor; Protein kinase A; Rp-cAMPS; Hippocampus
Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells
Keywords: مهار کننده MEK; MEK inhibitor; Microtubule-destabilizing agent; Apoptosis; Combination therapy; JNK
Detection of BRAF V600E mutation by pyrosequencing
Keywords: مهار کننده MEK; Pyrosequencing; BRAF; Lynch's syndrome; hereditary non-polyposis colorectal cancer; MEK inhibitor;
MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth
Keywords: مهار کننده MEK; Pancreatic cancer; Imatinib; MEK inhibitor; MEK–MAPK; Growth inhibition
Retinoid X receptor α is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of 9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells
Keywords: مهار کننده MEK; 9-cis RA; MEK inhibitor; RXRα; Apoptosis; HL-60; HL-60R
Pyrrolopyridazine MEK inhibitors
Keywords: مهار کننده MEK; MEK inhibitor; MEK1; Pyrrolopyridazine
Elevated expression of ERK 2 in human tumor cells chronically treated with PD98059
Keywords: مهار کننده MEK; MEK inhibitor; Chronic exposure; ERK 2; Tumor cells; Proliferation
Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors
Keywords: مهار کننده MEK; MEK inhibitor; MEK-1; MEK-2; Isothiazole carboxamidine; Allosteric inhibitors
Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death
Keywords: مهار کننده MEK; ERK pathway; MEK inhibitor; HDAC inhibitor; Apoptosis; Reactive oxygen species; Combination therapy